Last updated: March 6, 2023
Sponsor: University Hospital Inselspital, Berne
Overall Status: Active - Recruiting
Phase
N/A
Condition
Alzheimer's Disease
Amyloidosis
Neurologic Disorders
Treatment
N/AClinical Study ID
NCT05734378
2020-02535
Ages > 16 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Hypertensive deep perforator arteriolopathy (DPA), clinically symptomatic with eitherICH, ischaemic stroke, cognitive impairment or severe radiological manifestation (Fazekas ≥II)
- Cerebral amyloid angiopathy (CAA according to modified Boston or Edinburgh criteria),clinically symptomatic with either ICH (including cSAH), amyloid spells, cognitiveimpairment or severe radiological manifestation (CMB≥2)
- Other SVD (i.e. CADASIL or other sporadic or genetic SVD)
Exclusion
Exclusion Criteria:
- Life expectancy of <6 months due to not-SVD related causes (i.e. cancer)
- Patient is unlikely to attend follow-up visits
Study Design
Total Participants: 900
Study Start date:
December 01, 2020
Estimated Completion Date:
November 30, 2030
Connect with a study center
Department of Neurology, Inselspital Bern University Hospital
Bern, 3010
SwitzerlandActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.